Form 4: Cyclacel Pharmaceuticals Interim CEO David E. Lazar Converts Preferred Stock, Sells Common Stock in Private Transaction

Interim CEO David E. Lazar converted Series C and D Preferred Stock into common stock and subsequently sold a large block of common stock in a private transaction.

Summary

• David E. Lazar, Interim CEO of Cyclacel Pharmaceuticals, converted 1,000,000 shares of Series C Convertible Preferred Stock into 2,650,000 shares of common stock on February 26, 2025.
• On the same day, Lazar also converted 1,745,262 shares of Series D Convertible Preferred Stock into 191,978,820 shares of common stock.
• Following these conversions, Lazar sold 194,628,820 shares of common stock in a private transaction for $5,500,000, at a price of $0.0283 per share.
• Lazar directly owns all the shares.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the transactions themselves are not inherently negative, the large sale of common stock by the Interim CEO could be perceived as a lack of confidence in the company's future prospects, potentially leading to a negative market reaction.

Risks

• The sale of a large block of shares by the Interim CEO could create downward pressure on the stock price.
• The private transaction may not reflect the true market value of the shares.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The conversion of preferred stock into common stock and subsequent sale is a notable event that investors may interpret in various ways depending on the company's overall financial health and strategic direction.

Comparison to Industry Standards

• Comparing this transaction to similar insider sales in comparable pharmaceutical companies would require analyzing the size of the sale relative to the insider's holdings, the company's market capitalization, and recent stock performance.
• For example, if other pharmaceutical companies' CEOs have recently sold similar percentages of their holdings after converting preferred stock, this could be seen as a normal liquidity event.
• However, if this sale is significantly larger or occurs during a period of financial distress for Cyclacel, it could raise concerns among investors.

Stakeholder Impact

• Shareholders may be concerned about the potential downward pressure on the stock price due to the large sale.
• Employees may be concerned about the implications of the sale for the company's stability and future prospects.

Key Dates